Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
9.47
+0.06 (0.69%)
At close: Apr 10, 2026, 4:00 PM EDT
9.45
-0.02 (-0.16%)
After-hours: Apr 10, 2026, 4:10 PM EDT
Daxor Revenue
In the year 2025, Daxor had annual revenue of $26.69K, down -77.71%. Daxor had revenue of $8.34K in the half year ending December 31, 2025, a decrease of -89.88%.
Revenue (ttm)
$26.69K
Revenue Growth
-77.71%
P/S Ratio
2,066.65
Revenue / Employee
$593
Employees
45
Market Cap
55.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.69K | -93.03K | -77.71% |
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanara MedTech | 103.12M |
| Harvard Bioscience | 86.55M |
| Retractable Technologies | 38.27M |
| Precision Optics Corporation | 24.42M |
| Nephros | 18.79M |
| Ekso Bionics Holdings | 12.80M |
| Nyxoah | 11.76M |
| Milestone Scientific | 8.97M |
DXR News
- 3 days ago - Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center - GlobeNewsWire
- 16 days ago - Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 - GlobeNewsWire
- 25 days ago - Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - GlobeNewsWire
- 4 weeks ago - Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress - GlobeNewsWire
- 4 weeks ago - Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewsWire
- 5 weeks ago - Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - GlobeNewsWire
- 6 weeks ago - Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - GlobeNewsWire
- 2 months ago - Daxor Corporation Announces $9 Million Registered Direct Offering - GlobeNewsWire